MX2009000656A - Acidos nucleicos que se fijan a sdf-i. - Google Patents

Acidos nucleicos que se fijan a sdf-i.

Info

Publication number
MX2009000656A
MX2009000656A MX2009000656A MX2009000656A MX2009000656A MX 2009000656 A MX2009000656 A MX 2009000656A MX 2009000656 A MX2009000656 A MX 2009000656A MX 2009000656 A MX2009000656 A MX 2009000656A MX 2009000656 A MX2009000656 A MX 2009000656A
Authority
MX
Mexico
Prior art keywords
sdf
nucleic acid
nucleic acids
binding nucleic
acid molecules
Prior art date
Application number
MX2009000656A
Other languages
English (en)
Spanish (es)
Inventor
Sven Klussmann
Dirk Eulberg
Christian Maasch
Klaus Buchner
Florian Jarosch
Werner Purschke
Nicole Dinse
Original Assignee
Noxxon Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag
Publication of MX2009000656A publication Critical patent/MX2009000656A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6834Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/16Aptamers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
MX2009000656A 2006-07-18 2007-07-18 Acidos nucleicos que se fijan a sdf-i. MX2009000656A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06014957 2006-07-18
PCT/EP2007/006387 WO2008009437A2 (en) 2006-07-18 2007-07-18 Sdf-i binding nucleic acids

Publications (1)

Publication Number Publication Date
MX2009000656A true MX2009000656A (es) 2009-03-25

Family

ID=38947372

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009000656A MX2009000656A (es) 2006-07-18 2007-07-18 Acidos nucleicos que se fijan a sdf-i.

Country Status (16)

Country Link
US (5) US8314223B2 (enExample)
EP (1) EP2041282B1 (enExample)
JP (1) JP5380287B2 (enExample)
KR (2) KR101466931B1 (enExample)
CN (2) CN103555725B (enExample)
AR (1) AR061929A1 (enExample)
AU (1) AU2007276435C1 (enExample)
BR (1) BRPI0714844B8 (enExample)
CA (1) CA2658267C (enExample)
DK (1) DK2041282T3 (enExample)
ES (1) ES2663404T3 (enExample)
MX (1) MX2009000656A (enExample)
PL (1) PL2041282T3 (enExample)
PT (1) PT2041282T (enExample)
RU (1) RU2590709C2 (enExample)
WO (1) WO2008009437A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008009437A2 (en) 2006-07-18 2008-01-24 Noxxon Pharma Ag Sdf-i binding nucleic acids
KR101589442B1 (ko) * 2007-08-06 2016-02-01 녹손 파르마 아게 에스디에프-1 결합형 핵산 및 이의 용도
JP5463621B2 (ja) * 2008-02-27 2014-04-09 ソニー株式会社 標的物質の定量方法
US8710021B2 (en) * 2008-06-11 2014-04-29 Bionucleon S.R.L. Inhibition of HRP-3 using modified oligonucleotides
TWI578992B (zh) * 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素(hepcidin)結合之核酸類
WO2012025251A1 (en) * 2010-08-27 2012-03-01 Noxxon Pharma Ag Nucleic acids for treatment of chronic complications of diabetes
AU2011300818B2 (en) * 2010-09-09 2015-11-12 TME Pharma AG SDF-1 binding nucleic acids and the use thereof in cancer treatment
EP2633053A1 (en) * 2010-10-29 2013-09-04 Noxxon Pharma AG Use of hepcidin binding nucleic acids for depletion of hepcidin from the body
CN104661664B (zh) 2012-07-13 2020-07-03 波涛生命科学有限公司 手性控制
WO2016096640A2 (en) * 2014-12-17 2016-06-23 Cancer Research Technology Ltd Anti-cxcl12 antibody molecules and their uses
US11371045B2 (en) * 2016-04-15 2022-06-28 Noxxon Pharma Ag Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors
US11221270B2 (en) * 2018-02-27 2022-01-11 Kevan M Evans Method and apparatus for detecting slow leaks
WO2021178923A1 (en) 2020-03-06 2021-09-10 Drinksavvy, Inc. Devices and methods for detecting a target analyte of interest
CN115997122A (zh) 2020-06-26 2023-04-21 拉夸里亚创药株式会社 类维生素a与癌治疗剂的组合疗法有效的癌患者的选择方法、及类维生素a与癌治疗剂的组合药物
WO2023154452A1 (en) 2022-02-11 2023-08-17 Waypoint Bio, Inc. Cellular staining probes for analyte detection

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
IE920562A1 (en) * 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for biomolecules and method of making
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
EP1072273B1 (en) * 1998-03-24 2006-07-26 Chugai Seiyaku Kabushiki Kaisha Vascularization inhibitors
US6670149B1 (en) * 1999-03-01 2003-12-30 Millennium Pharmaceuticals, Inc. TWIK-5 potassium channel nucleic acids and uses therefor
US6949243B1 (en) 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
EP1133988A1 (en) 2000-03-11 2001-09-19 Biognostik Gesellschaft für biomolekulare Diagnostik mbH Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene
EP1717583A3 (en) * 2001-06-07 2007-10-10 ChemoCentryx Inc Cell migration assay
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
GB0225833D0 (en) 2002-11-06 2002-12-11 Univ Leeds Nucleic acid ligands and uses therefor
ES2729826T3 (es) 2004-09-23 2019-11-06 Arc Medical Devices Inc Composiciones farmacéuticas y métodos relacionados para inhibir adherencias fibrosas o enfermedad inflamatoria usando fucanos con bajo contenido de sulfato
DE502005009920D1 (de) * 2004-11-29 2010-08-26 Noxxon Pharma Ag Vasopressin bindende l-nukleinsäure
BRPI0707446A2 (pt) 2006-02-02 2011-05-03 Allergan Inc composições e métodos para o tratamento de doença oftálmica
WO2008009437A2 (en) 2006-07-18 2008-01-24 Noxxon Pharma Ag Sdf-i binding nucleic acids
SG178712A1 (en) 2006-10-02 2012-03-29 Medarex Inc Human antibodies that bind cxcr4 and uses thereof
JP5296701B2 (ja) 2006-11-30 2013-09-25 ユニバーシティ オブ バージニア パテント ファウンデーション 線維性疾患および線維増殖性疾患を処置および診断するための方法
KR101589442B1 (ko) 2007-08-06 2016-02-01 녹손 파르마 아게 에스디에프-1 결합형 핵산 및 이의 용도
US20090274687A1 (en) 2008-05-02 2009-11-05 University Of Miami Attenuation of hypoxia induced cardiovascular disorders

Also Published As

Publication number Publication date
RU2590709C2 (ru) 2016-07-10
EP2041282A2 (en) 2009-04-01
PL2041282T3 (pl) 2018-07-31
EP2041282B1 (en) 2018-01-03
AR061929A1 (es) 2008-10-01
BRPI0714844B8 (pt) 2023-04-18
AU2007276435B2 (en) 2013-01-24
CN101506364A (zh) 2009-08-12
CN103555725A (zh) 2014-02-05
DK2041282T3 (en) 2018-04-16
US20180163207A1 (en) 2018-06-14
HK1131184A1 (en) 2010-01-15
KR20090039717A (ko) 2009-04-22
KR101466931B1 (ko) 2014-12-02
CA2658267C (en) 2021-03-30
US9035038B2 (en) 2015-05-19
US20110112172A1 (en) 2011-05-12
BRPI0714844A2 (pt) 2013-11-26
JP2009543567A (ja) 2009-12-10
RU2009105494A (ru) 2010-08-27
AU2007276435C1 (en) 2013-06-13
US20210139909A1 (en) 2021-05-13
WO2008009437A3 (en) 2008-03-27
US9822369B2 (en) 2017-11-21
WO2008009437A2 (en) 2008-01-24
ES2663404T3 (es) 2018-04-12
CN101506364B (zh) 2013-10-30
CA2658267A1 (en) 2008-01-24
CN103555725B (zh) 2017-05-24
US20130041019A1 (en) 2013-02-14
KR20130090428A (ko) 2013-08-13
US8314223B2 (en) 2012-11-20
BRPI0714844B1 (pt) 2019-10-01
AU2007276435A1 (en) 2008-01-24
JP5380287B2 (ja) 2014-01-08
KR101561652B1 (ko) 2015-10-20
PT2041282T (pt) 2018-03-13
US20150232853A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
MX2009000656A (es) Acidos nucleicos que se fijan a sdf-i.
MX2010003109A (es) Acidos nucleicos de enlace c5a.
MX337801B (es) Acidos nucleicos que se enlazan on mcp-1.
WO2009035303A3 (en) Bacteriophage or lytic protein derived from the bacteriophage which effective for treatment of staphylococcus aureus biofilm
WO2007062160A8 (en) Methods and compositions for sequencing a nucleic acid
MX346862B (es) Secuencias consenso de envoltura de vih y método para usar las mismas.
WO2009139630A3 (en) Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means
IN2014CN02050A (enExample)
WO2009004315A8 (en) Isolated peptides and uses thereof
WO2004099228A3 (en) Variants of beta-glucosidases
WO2009047992A1 (ja) Udp-グルクロン酸転移酵素およびそれをコードするポリヌクレオチド
WO2008146745A1 (ja) 新規なリゾホスファチジン酸アシル基転移酵素遺伝子
IL201963A (en) Vectors for multi-gene expression, host cell and pharmacy preparation containing and using them
MX2009000654A (es) Medios para inhibir la expresion de la cinasa de proteina 3.
MX2008009493A (es) Peptido novedoso y uso del mismo.
WO2008113536A8 (en) Neurotrophic peptides
WO2010057242A3 (de) Vakzin
WO2008087224A3 (en) Mutated netrin 4, fragments thereof and uses thereof as drugs
WO2008047370A3 (en) Compositions and methods for inducing angiogenesis
WO2010026219A3 (en) New tomato ethylene response factors and uses thereof
WO2008017073A3 (en) Vector systems
MX2008004899A (es) Compuestos y métodos para partículas de condensado de ácido ribonucleico de péptido para terapéuticos de arn.
WO2007121946A3 (en) Means for inhibiting the expression of cd31
WO2007066018A3 (fr) Peptides qui peuvent se lier a la proteine nef et leurs applications pharmaceutiques
GB0423126D0 (en) Protein

Legal Events

Date Code Title Description
FG Grant or registration